Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Metagenomi (MGX) Change in Accured Expenses (2023 - 2025)

Historic Change in Accured Expenses for Metagenomi (MGX) over the last 3 years, with Q3 2025 value amounting to $4.0 million.

  • Metagenomi's Change in Accured Expenses rose 53967.21% to $4.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year increase of 27584.1%. This contributed to the annual value of -$893000.0 for FY2024, which is 15481.89% down from last year.
  • Per Metagenomi's latest filing, its Change in Accured Expenses stood at $4.0 million for Q3 2025, which was up 53967.21% from $172000.0 recorded in Q2 2025.
  • Metagenomi's 5-year Change in Accured Expenses high stood at $4.0 million for Q3 2025, and its period low was -$3.0 million during Q1 2024.
  • Moreover, its 3-year median value for Change in Accured Expenses was $172000.0 (2025), whereas its average is $207545.5.
  • As far as peak fluctuations go, Metagenomi's Change in Accured Expenses crashed by 23969.47% in 2024, and later soared by 53967.21% in 2025.
  • Metagenomi's Change in Accured Expenses (Quarter) stood at $902000.0 in 2023, then crashed by 135.25% to -$318000.0 in 2024, then soared by 1365.09% to $4.0 million in 2025.
  • Its last three reported values are $4.0 million in Q3 2025, $172000.0 for Q2 2025, and -$2.6 million during Q1 2025.